Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VU6046180
- Development stage
- Unknown
- Lead developer
- Vanderbilt University
01
Overview
VU6046180: sourced facts only. name: "A high-throughput screening (HTS) campaign identified a selective mGlu3 PAM VU6046180/BI'3690 (7) containing a benzoxazine core (an orthogonal chemotype to previously reported thiophene tool compound VU6053371/BI'8809 (6))." [PMID:42621469]; target: "A high-throughput screening (HTS) campaign identified a selective mGlu3 PAM VU6046180/BI'3690 (7) containing a benzoxazine core (an orthogonal chemotype to previously reported thiophene tool compound VU6053371/BI'8809 (6))." [PMID:42621469]; developer: "Warren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States." [PMID:42621469]
02
Targets
GRM3 (mGluR3)
Beyond the preview
Go deeper on VU6046180.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VU6046180.